
## REVIEW



## Bacteriophages of *Mycobacterium tuberculosis*, their diversity, and potential therapeutic uses: a review



Fatemeh Zeynali kelishomi<sup>1</sup>, Susan Khanjani<sup>1</sup>, Fatemeh Fardsanei<sup>1</sup>, Hediyeh Saghi Sarabi<sup>1</sup>, Farhad Nikkhahi<sup>1\*</sup> and Behzad Dehghani<sup>2</sup>

## Abstract

Tuberculosis (TB) caused by *Mycobacterium tuberculosis (M. tuberculosis*) is a highly infectious disease and worldwide health problem. Based on the WHO TB report, 9 million active TB cases are emerging, leading to 2 million deaths each year. The recent emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains emphasizes the necessity to improve novel therapeutic plans. Among the various developing anti-bacterial approaches, phage therapy is thought to be a precise hopeful resolution. Mycobacteriophages are viruses that infect bacteria such as *Mycobacterium* spp., containing the *M. tuberculosis* complex. Phages and phage-derived proteins can act as promising antimicrobial agents. Also, phage cocktails can broaden the spectrum of lysis activity against bacteria. Recent researches have also shown the effective combination of antibiotics and phages to defeat the infective bacteria. There are limitations and concerns about phage therapy. For example, human immune response to phage therapy, transferring antibiotic resistance genes, emerging resistance to phages, and safety issues. So, in the present study, we introduced mycobacteriophages, their use as therapeutic agents, and their advantages and limitations as therapeutic applications.

Keywords: Mycobacterium tuberculosis, Drug resistance, Mycobacteriophages, Phage therapy

## Background

Tuberculosis (TB) caused by *Mycobacterium tuberculosis* (*M. tuberculosis*) is a highly infectious disease and worldwide health problem, with a high mortality rate and nearly  $\sim 1.6$  million recognized deaths in 2021. It has harmed humankind for approximately 9000 years, with the first report dating back more than 3000 years ago in India and China [1, 2]. TB had a notable effect on social health owing to decreased influence and a more negligible therapeutic effect with mycobacterial therapy. The quick prevalence of disease and the warning development

\*Correspondence: farhadnikkhahi@gmail.com

<sup>1</sup> Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran

of drug resistance, particularly the appearance of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains, have called the alarm to gain novel effective drugs; thus, finding a substitute line for the controlling and management of TB has become essential. One of the main features of Myco*bacterium* is that it produces highly resistant mutants under selective pressure conditions caused by antibiotics. The following evolutionary achievement of resistant mutants depends mostly on the mutant's resistance rate and ability and selective elimination owing to antibiotic therapy. Among the various developing antibacterial approaches, phage therapy is thought to be a precise hopeful resolution. Bacteriophages (phages) are a type of viruses that infect bacteria and are very widespread in the environment. Bacteriophages can be used clinically



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Full list of author information is available at the end of the article